Brief: Medigene: Clinical Data From Interim Analysis Of Phase I/II Trial With DC Vaccine

Medigene AG

17/06/2019 06:32

June 17 (Reuters) - Medigene AG  MDG1k.DE :
    * INTERIM ANALYSIS FROM ONGOING PHASE I/II CLINICAL TRIAL
WITH DC
VACCINES IN AML PATIENTS PRESENTED AT EHA
    * EXCELLENT SAFETY AND TOLERABILITY PROFILE
    * ENCOURAGING DATA ON OVERALL SURVIVAL AND PROGRESSION-FREE
SURVIVAL
    * VERY GOOD FEASIBILITY FOR MANUFACTURE OF VACCINES FROM
PATIENT-DERIVED CELLS

Source text for Eikon:  ID:nPexYX7BJa 
Further company coverage:  MDG1k.DE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))